BiotechTube

Midazolam + AZD5718

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiovascular Disease

Conditions

Cardiovascular Disease

Trial Timeline

Jul 30, 2020 → Oct 19, 2020

NCT ID
NCT04492709

About Midazolam + AZD5718

Midazolam + AZD5718 is a phase 1 stage product being developed by AstraZeneca for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04492709. Target conditions include Cardiovascular Disease.

What happened to similar drugs?

20 of 20 similar drugs in Cardiovascular Disease were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Empagliflozin + PlacebosEli LillyApproved
✅Aspirin + Placebo + ticagrelorAstraZenecaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04492709Phase 1Completed

Competing Products

20 competing products in Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lorcaserin hydrochloride + PlaceboEisaiApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26